Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study

• Main Authors: Riccardo G. Borroni (Author), Piergiorgio Malagoli (Author), Luigi Gargiulo (Author), Mario Valenti (Author), Giulia Pavia (Author), Paola Facheris (Author), Emanuela Morenghi (Author), Isotta Giunipero di Corteranzo (Author), Alessandra Narcisi (Author), Michela Ortoncelli (Author), Paolo Dapavo (Author), Antonio Costanzo (Author)
• Format: Knjiga
• Izdano: Medical Journals Sweden, 2021-11-01T00:00:00Z.
• Teme: article
• Online dostop: Connect to this object online.

Risankizumab is a humanized monoclonal antibody that binds the p19 subunit of interleukin-23. It is approved for treatment of moderate-severe chronic plaque psoriasis. This retrospective study included 66 consecutive adults with moderate-to-severe psoriasis vulgaris treated with risankizumab in mono...